AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.01+6.85 (+2.36%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB60.95+1.50 (+2.52%) ▲|V422.16-0.49 (-0.12%) ▼|VZ46.06+0.37 (+0.81%) ▲|WFC85.49+1.55 (+1.85%) ▲|WMT125.66+0.14 (+0.11%) ▲|XOM164.73-1.14 (-0.69%) ▼|AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.01+6.85 (+2.36%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB60.95+1.50 (+2.52%) ▲|V422.16-0.49 (-0.12%) ▼|VZ46.06+0.37 (+0.81%) ▲|WFC85.49+1.55 (+1.85%) ▲|WMT125.66+0.14 (+0.11%) ▲|XOM164.73-1.14 (-0.69%) ▼|
10.3 C
New York
Tuesday, November 10, 2026

Tag: results

Brookfield Renewable to Increase Stake in a Strategic Portfolio of Hydro Assets

BROOKFIELD, News, July 18, 2025 (GLOBE NEWSWIRE) -- Brookfield Renewable (NYSE: BEP, BEPC; TSX: BEP.UN, BEPC) (“Brookfield Renewable”) today has announced that it will invest up to $1 billion to increase its equity interest to approximately 38% in Isagen S.A. E.S.P. (“Isagen”).

Rogers Announces Pricing of Cash Tender Offers for Eight Series of U.S. Dollar Debt Securities

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) today announced the pricing terms of its previously announced separate offers (the “Offers”) to purchase for cash any and all of the outstanding notes of each series listed in the table below (collectively, the “Notes”), up to a maximum of US$1,250,000,000 aggregate Total Consideration (as defined below). Subject to the Consideration Cap Condition (as defined below), the series of Notes that are purchased in the Offers will be based on the acceptance priority levels (each, an “Acceptance Priority Level”) set forth in the table below. If a given series of Notes is accepted for purchase pursuant to the Offers, all Notes of that series that are validly tendered and not validly withdrawn will be accepted for purchase. No series of Notes will be subject to proration pursuant to the Offers.

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection...

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.

Encompass Health announces plans to build a 40-bed inpatient rehabilitation hospital in Cleveland, Tennessee

BIRMINGHAM, Ala. and CLEVELAND, Tenn., July 18, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced plans to build a freestanding, 40-bed inpatient rehabilitation...

Best Financial Modeling Course (2025): Corporate Finance Institute Recognized as Top Financial Training Program in Report by Expert Consumers

NEW YORK, July 18, 2025 /PRNewswire/ -- The Financial Modeling & Valuation Analyst (FMVA®) certification by Corporate Finance Institute (CFI) has been named the...

Berks Homes Unveils Elizabeth Village: A New Townhome Community in Lower Paxton Township, Harrisburg, PA

HARRISBURG, Pa., July 18, 2025 /PRNewswire/ -- Berks Homes, a trusted local builder for over 50 years, is excited to announce the grand opening...

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Andrew Peller Ltd. Announces Timing of Q1 2026 Results & Conference Call

GRIMSBY, Ontario, July 18, 2025 (GLOBE NEWSWIRE) -- Andrew Peller Limited (ADW.A / ADW.B) will issue its financial results for the three months ended June 30, 2025, after close of market on Wednesday, August 6, 2025. Management will host a conference call to discuss the financial results on Thursday, August 7, 2025, at 10:00 a.m. (ET), followed by a question-and-answer period.

Hapbee Reports First-Ever Quarterly Profit in Q2 2025 and Achieves Third Consecutive Quarter of Growth

Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter
Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter 

Timbercreek Financial Announces Conference Call to Discuss Second Quarter Financial Results

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) will hold a conference call and live audio webcast at 1:00 p.m. (ET) on Thursday, July 31, 2025, to discuss financial results for the quarter ended June 30, 2025. The financial results will be released on Wednesday, July 30, 2025, after the markets close. Interested parties are invited to participate in the call with management which will be followed by a question and answer period with analysts.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResults